Who owns CRISPR Therapeutics AG?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of CRSP from SEC Form 13F filings across 525 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 525 institutions disclosed 76.3M shares of CRISPR Therapeutics AG worth $5.47B — about 78.8% of shares outstanding; the largest disclosed holder is ARK Investment Management LLC. Source: SEC Form 13F filings, parsed by EvidInvest.
525
13F holders
$5.47B
value, 2026 filers
78.8%
of shares outstanding (76.3M sh)
92
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of CRSP's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | ARK Investment Management LLC | 9.5M | $516.0M | 3.4% | 9.8% | -16.4% |
| 2 | BlackRock, Inc. | 8.3M | $455.4M | 0.0% | 8.6% | +8.7% |
| 3 | Orbis Allan Gray Ltd | 5.4M | $297.2M | 1.0% | 5.6% | -10.8% |
| 4 | Capital World Investors | 4.7M | $259.0M | 0.0% | 4.9% | +0.5% |
| 5 | STATE STREET CORP | 4.3M | $235.7M | 0.0% | 4.5% | +8.5% |
| 6 | GSK plc | 3.2M | $175.7M | 29.2% | 3.3% | 0.0% |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 2.5M | $136.9M | 0.0% | 2.6% | +5.6% |
| 8 | T. Rowe Price Investment Management, Inc. | 2.1M | $112.0M | 0.1% | 2.1% | -30.5% |
| 9 | SR One Capital Management, LP | 2.0M | $111.2M | 10.7% | 2.1% | 0.0% |
| 10 | TWO SIGMA INVESTMENTS, LP | 2.0M | $108.5M | 0.1% | 2.1% | +34.1% |
| 11 | FMR LLC | 1.9M | $104.1M | 0.0% | 2% | -2.4% |
| 12 | Sumitomo Mitsui Trust Group, Inc. | 1.7M | $93.8M | 0.1% | 1.8% | -7.2% |
| 13 | Amova Asset Management Americas, Inc. | 1.7M | $93.8M | 1.2% | 1.8% | -7.2% |
| 14 | EcoR1 Capital, LLC | 1.4M | $75.8M | 3.7% | 1.4% | 0.0% |
| 15 | UBS Group AG | 1.3M | $71.9M | 0.0% | 1.4% | -25.2% |
| 16 | Capital International Investors | 1.3M | $69.2M | 0.0% | 1.3% | +6.9% |
| 17 | VANGUARD CAPITAL MANAGEMENT LLC | 1.2M | $64.5M | 0.0% | 1.2% | +3.4% |
| 18 | BANK OF AMERICA CORP /DE/ | 1.2M | $63.0M | 0.0% | 1.2% | +17.5% |
| 19 | NEA Management Company, LLC | 1.1M | $57.7M | 3.6% | 1.1% | 0.0% |
| 20 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.1M | $57.7M | 0.0% | 1.1% | +1.8% |
| 21 | D. E. Shaw & Co., Inc.NEW | 893,812 | $48.7M | 0.0% | 0.9% | new |
| 22 | MORGAN STANLEY | 879,949 | $48.0M | 0.0% | 0.9% | +31.7% |
| 23 | NORTHERN TRUST CORP | 863,091 | $47.1M | 0.0% | 0.9% | +7.6% |
| 24 | VANGUARD PORTFOLIO MANAGEMENT LLC | 648,713 | $35.4M | 0.0% | 0.7% | +18.6% |
| 25 | VANGUARD FIDUCIARY TRUST CO | 570,040 | $31.1M | 0.0% | 0.6% | +5.0% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.